Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation (NASDAQ:CELG) stock performance was 0.88% in last session and finished … Continue reading Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now directly owns 280,000 shares in the company, valued at approximately … Continue reading Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Stocks to watch: Cavium Inc (NASDAQ:CAVM), Omeros Corporation (NASDAQ:OMER), EDAP (NASDAQ:EDAP), BGC Partners (NASDAQ:BGCP), Intersil Corp (NASDAQ:ISIL)

Cavium, Inc. (NASDAQ:CAVM), a leading provider of semiconductor products that enable intelligent processing for enterprise, data center, cloud, wired and wireless networking, on 03 June 2014 announced the introduction of a new game changing category of processors that are workload optimized for a range of applications in the cloud and data center. The 2.5GHz 48 core ThunderX is the world’s highest performing low-power 64-bit ARMv8 … Continue reading Stocks to watch: Cavium Inc (NASDAQ:CAVM), Omeros Corporation (NASDAQ:OMER), EDAP (NASDAQ:EDAP), BGC Partners (NASDAQ:BGCP), Intersil Corp (NASDAQ:ISIL)

Gilead Sciences GILD NASDAQ:GILD

Trending Stocks: OmniVision Technologies, Inc. (NASDAQ:OVTI), Omeros Corporation (NASDAQ:OMER), JD.Com Inc (ADR) (NASDAQ:JD), Halliburton Company (NYSE:HAL)

OmniVision Technologies Inc (NASDAQ:OVTI) was upgraded by Northland Securities from a “market perform” rating to an “outperform” rating in a research note issued on Friday. The firm currently has a $28.00 price objective on the stock, up from their previous price objective of $21.00. Northland Securities’ price objective suggests a potential upside of 39.03% from the company’s current price. OmniVision Technologies, Inc. (NASDAQ:OVTI) stock performance … Continue reading Trending Stocks: OmniVision Technologies, Inc. (NASDAQ:OVTI), Omeros Corporation (NASDAQ:OMER), JD.Com Inc (ADR) (NASDAQ:JD), Halliburton Company (NYSE:HAL)

Biotech Gainers: Cerus Corporation (NASDAQ:CERS), Omeros Corporation (NASDAQ:OMER), Durata Therapeutics Inc (NASDAQ:DRTX), Aastrom Biosciences Inc (NASDAQ:ASTM)

Cerus Corporation (NASDAQ:CERS) and a pharmaceutical unit of Nipro Corporation announced a collaboration agreement. The collaboration will lead to the development of efficient and easy-to-use disposable kit for red cells. The project will benefit from the proprietary technology of Nipro towards the creation a red cell disposable kit that suits the needs of small and large blood centers. Cerus Corporation (NASDAQ:CERS) stock performance was 7.55% … Continue reading Biotech Gainers: Cerus Corporation (NASDAQ:CERS), Omeros Corporation (NASDAQ:OMER), Durata Therapeutics Inc (NASDAQ:DRTX), Aastrom Biosciences Inc (NASDAQ:ASTM)